Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073142 | 0.81 | TSHR (0.57) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14072945 | 0.79 | SMN1; SMN2 (0.69) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14072944 | 0.78 | TSHR (0.53) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL8192214 | 0.78 | TSHR (0.53) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073181 | 0.78 | TSHR (0.53) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073146 | 0.77 | SMN1; SMN2 (0.61) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073367 | 0.77 | TSHR (0.53) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073116 | 0.76 | PARP1 (0.62) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14072985 | 0.75 | TSHR (0.85) | PARP1TSHRMAOAMMP8MMP13 | |
| SCHEMBL14073051 | 0.75 | PARP1 (0.70) | PARP1TSHRMAOAMMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109180-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | PARP1 327/4885TSHR 4343/4885MAOA 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.